Navigation Links
Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation

WASHINGTON, Feb. 5 /PRNewswire-USNewswire/ -- Notice is hereby given that Finkelstein Thompson LLP has filed a Class Action lawsuit in the United State District Court for the Western District of Washington on behalf of a class (the "Class") consisting of all persons or entities who purchased or otherwise acquired the common stock of CellCyte Genetics Corporation ("CellCyte" or the "Company") (OTC Bulletin Board: CCYG.OB) between April 6, 2007 and January 9, 2008 inclusive (the "Class Period").

A copy of the Complaint is available from the court or from Finkelstein Thompson LLP. Please call us toll-free at (877) 337-1050 to discuss this action or to obtain a copy of the Complaint. You may also contact us by email at, or visit our website at

The Complaint alleges that CellCyte misled the investing public throughout the Class Period by publishing false information about the history and experience of the company's chief executive officer Gary A. Reys. Specifically, Plaintiff alleges that CellCyte misrepresented Reys' credentials on the Company's website and in SEC filings, particularly regarding Reys' educational background, his status as a certified public accountant in the state of Washington, and his prior role in the initial public offerings of var2ious pharmaceutical companies.

According to the Complaint, CellCyte made false and misleading statements about Reys to the SEC and potential investors. The truth regarding Reys' credentials began to surface in early January after news media inquiries into Reys' background. Shortly after these inquiries, CellCyte removed numerous claims regarding Reys' credentials from the Company's website.

As a result of Defendant's misrepresentations and omissions, CellCyte's stock traded at inflated levels during the Class Period. Once the truth behind Reys was revealed, CellCyte shares plunged 55% in unusually heavy trading on January 8 and 9. The stock fell as low as $2.15 on January 9, 2008, down from a high of $7.02 just days before.

Plaintiff seeks to recover damages on behalf of Class members and is represented by Finkelstein Thompson LLP. Finkelstein Thompson LLP has spent almost three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, in the past decade, the firm has served leadership roles in cases that have recovered over $1 billion for investors and consumers.

If you are a member of the class, you may request that the Court appoint you as lead plaintiff by no later than March 14, 2008. A lead plaintiff is a class member appointed by the Court to direct the litigation on behalf of the class. Although a class member need not be appointed as a lead plaintiff to receive a proportionate share of any proceeds of the litigation, lead plaintiffs make important decisions that could affect the prosecution of the class claims, including decisions concerning settlement. The securities laws create a rebuttable presumption that the plaintiff with the largest financial interest in the litigation is the most adequate to serve as a lead plaintiff. Any member of the purported class may move the Court to serve as lead plaintiff through the counsel of their choice and returning a form to counsel or communicating with counsel is not necessary to participate in any recovery.

If you are a CellCyte shareholder and wish to discuss the case, please contact our Washington, D.C. office toll-free at (877) 337-1050, or by email at

SOURCE Finkelstein Thompson LLP
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
2. MHA Announces: Tommy Thompson to be Keynote Speaker at The MHA 5th Annual Business Summit
3. SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors
4. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
5. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
6. CardioTech Announces Conference Call on February 12 at 2:30 PM Eastern for Third Quarter of Fiscal 2008
7. NeoStem Announces NY State License for Adult Stem Cell Collection
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
10. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... SAN FRANCISCO , June 22, 2016  Amgen ... platinum sponsorship of the QB3@953 life sciences ... improve human health. The shared laboratory space at QB3@953 ... startups overcome a key obstacle for many early stage ... As part of the sponsorship, Amgen launched two "Amgen ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
Breaking Biology News(10 mins):